免费查询更多18f-bms-986229示踪剂详细参数、实时报价、行情走势、优质商品批发/供应信息等,您还可以发布询价信息。
BMS的18F-BMS-986229是以具有皮摩尔级PD-L1 亲和力的强效大环肽衍生PD-L1拮抗剂BMS-986189为起点设计的。根据 BMS-986189 和 PD-L1的共晶体结构,在肽的溶剂暴露部分加入了丙炔甘氨酸分子,可通过铜催化的叠氮-炔环加成反应标记这种大环肽。 18F-BMS-986229的合成路线 研究主要目的是评估全性和可行性,如果没有出现 ...
Patients were administered18F-BMS-986229 intravenously and underwent whole body PET/CT 60 minutes later. The primary endpoint was safety and feasibility.Results:Ten patients underwent PD-L1 PET imaging. All had adenocarcinoma, 70% had metastatic disease, 20% had locally advanced, unresectable tumors,...
BMS的18F-BMS-986229是以具有皮摩尔级PD-L1 亲和力的强效大环肽衍生PD-L1拮抗剂BMS-986189为起点设计的。根据 BMS-986189 和 PD-L1的共晶体结构,在肽的溶剂暴露部分加入了丙炔甘氨酸分子,可通过铜催化的叠氮-炔环加成反应标记这种大环肽。 18F-BMS-986229的合成路线 研究主要目的是评估全性和可行性,如果没有出现 ...
Determining PD-L1 status by whole body, non-invasive PD-L1 PET imaging with 18F-BMS-986229 tracer infusion may be a way to circumvent limitations to PD-L1 IHC such as poor tissue availability; discrepant PD-L1 IHC results among different tumors within the same patient; and inability to ...